{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:13:48Z","timestamp":1768029228293,"version":"3.49.0"},"reference-count":40,"publisher":"FapUNIFESP (SciELO)","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz J Med Biol Res"],"DOI":"10.1590\/1414-431x20176073","type":"journal-article","created":{"date-parts":[[2017,11,11]],"date-time":"2017-11-11T17:27:46Z","timestamp":1510421266000},"source":"Crossref","is-referenced-by-count":18,"title":["Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer"],"prefix":"10.1590","volume":"51","author":[{"given":"R.F.","family":"Yang","sequence":"first","affiliation":[{"name":"Shandong University,  China; Taian City Central Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Yu","sequence":"additional","affiliation":[{"name":"Taian City Central Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.Q.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Taian City Central Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.H.","family":"Wang","sequence":"additional","affiliation":[{"name":"Taian City Central Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Li","sequence":"additional","affiliation":[{"name":"Taian City Central Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Wang","sequence":"additional","affiliation":[{"name":"Taian City Central Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Taian City Central Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Han","sequence":"additional","affiliation":[{"name":"Taian City Central Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.X.","family":"Gao","sequence":"additional","affiliation":[{"name":"Taian City Central Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Taian City Central Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.M.","family":"Jiang","sequence":"additional","affiliation":[{"name":"Shandong University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2018]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal A","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.6004\/jnccn.2012.0130","article-title":"Non-small cell lung cancer","volume":"10","author":"Ettinger DS","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan JS","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1002\/cncr.25254","article-title":"Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer","volume":"116","author":"Hubbs JL","year":"2010","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/JCO.2011.40.1174","article-title":"Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer","volume":"31","author":"Welsh JW","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.radonc.2008.05.020","article-title":"A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision","volume":"88","author":"Davey P","year":"2008","journal-title":"Radiother Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2007.09.016","article-title":"A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118)","volume":"71","author":"Knisely JP","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11060-011-0590-9","article-title":"Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of <\/= 6 brain metastases: a multi-institutional phase II trial","volume":"105","author":"McHaffie DR","year":"2011","journal-title":"J Neurooncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijrobp.2007.06.074","article-title":"A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database","volume":"70","author":"Sperduto PW","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijrobp.2004.04.061","article-title":"Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial","volume":"61","author":"Verger E","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch TJ","year":"2004","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1158\/1078-0432.CCR-10-1588","article-title":"Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib","volume":"16","author":"Heon S","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2217\/fon.10.156","article-title":"The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer","volume":"6","author":"Neal JW","year":"2010","journal-title":"Future Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2016.01.005","article-title":"Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer","volume":"93","author":"Hirose T","year":"2016","journal-title":"Lung Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3892\/ol.2015.4066","article-title":"Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients","volume":"11","author":"Zhou BO","year":"2016","journal-title":"Oncol Lett"},{"key":"ref16","article-title":"Association of VEGF, CD-34, E-cadherin and MMP-9 expression of the primary non-small cell lung cancer lesion with brain metastatic lesion","author":"Milas I","year":"2004","journal-title":"Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon MS","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1078-0432.CCR-09-2439","article-title":"Bevacizumab safety in patients with central nervous system metastases","volume":"16","author":"Besse B","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara N","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-010-0200-2","article-title":"Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer","volume":"100","author":"De Braganca KC","year":"2010","journal-title":"J Neurooncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1093\/annonc\/mdu465","article-title":"REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours","volume":"25","author":"Levy C","year":"2014","journal-title":"Ann Oncol"},{"key":"ref22","first-page":"881","article-title":"[New guidelines to evaluate the response to treatment in solid tumors]","volume":"87","author":"Duffaud F","year":"2000","journal-title":"Bull Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy","volume":"47","author":"Trotti A","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref24","first-page":"14","article-title":"Results of surgical treatment of primary lung cancer with synchronous brain metastases","volume":"12","author":"Bella MJ","year":"2015","journal-title":"Kardiochir Torakochirurgia Pol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","article-title":"Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis","volume":"34","author":"Johung KL","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/annonc\/mdh276","article-title":"Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial","volume":"15","author":"Ceresoli GL","year":"2004","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2004.04.036","article-title":"Effect of gefitinib (\u2018Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer","volume":"46","author":"Hotta K","year":"2004","journal-title":"Lung Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3816\/CLC.2004.n.026","article-title":"Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases","volume":"6","author":"Namba Y","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1215\/15228517-2005-002","article-title":"EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib","volume":"8","author":"Shimato S","year":"2006","journal-title":"Neuro Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"909","DOI":"10.7314\/APJCP.2012.13.3.909","article-title":"Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study","volume":"13","author":"Zeng YD","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.lungcan.2008.10.028","article-title":"Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population","volume":"65","author":"Ma S","year":"2009","journal-title":"Lung Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ejca.2009.06.005","article-title":"Targeted therapies in the treatment of advanced\/metastatic NSCLC","volume":"45","author":"Pallis AG","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000074471","article-title":"Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine","volume":"65","author":"Berardi R","year":"2003","journal-title":"Oncology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/1476-4598-9-222","article-title":"Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated","volume":"9","author":"Park SY","year":"2010","journal-title":"Mol Cancer"},{"key":"ref35","first-page":"4300","article-title":"Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa)","volume":"62","author":"Huang SM","year":"2002","journal-title":"Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cllc.2012.06.004","article-title":"Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma","volume":"14","author":"Zhao J","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1586\/14737140.2015.1028376","article-title":"Bevacizumab in high-grade gliomas: past, present, and future","volume":"15","author":"Curry RC","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/neuonc\/nor223","article-title":"Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors","volume":"14","author":"Armstrong TS","year":"2012","journal-title":"Neuro Oncol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2011.36.5478","article-title":"Controversial role of bevacizumab in the development of venous thromboembolic events","volume":"29","author":"Hapani S","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-008-9718-y","article-title":"Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan","volume":"91","author":"Zuniga RM","year":"2009","journal-title":"J Neurooncol"}],"container-title":["Brazilian Journal of Medical and Biological Research"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/bjmbr\/v51n1\/1414-431X-bjmbr-1414-431X20176073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T14:01:26Z","timestamp":1581429686000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-879X2018000100606&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018]]}},"alternative-id":["S0100-879X2018000100606"],"URL":"https:\/\/doi.org\/10.1590\/1414-431x20176073","relation":{},"ISSN":["1414-431X","0100-879X"],"issn-type":[{"value":"1414-431X","type":"electronic"},{"value":"0100-879X","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"article-number":"e6073"}}